Suchergebnisse - "Shah, Rashmi R"

PubPharm (147)

61

Cardiovascular toxicity: understanding the issues, challenges and opportunities

enthalten in: Toxicology letters | 2013

von Shah, R.

62

Hepatotoxicity of tyrosine kinase inhibitors : clinical and regulatory perspectives

enthalten in: Drug safety | 2013

von Shah, R. | Morganroth, J. | Shah, D.

63

Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives

enthalten in: Medical toxicology | 2013

von Shah, R. | Morganroth, J. | Shah, D.

64

Tyrosine kinase inhibitors : their on-target toxicities as potential indicators of efficacy

enthalten in: Drug safety | 2013

von Shah, D. | Shah, R. | Morganroth, J.

65

Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives

enthalten in: Drug safety | 2013

von Shah, R. | Morganroth, J. | Shah, D.

66

Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy

enthalten in: Medical toxicology | 2013

von Shah, D. | Shah, R. | Morganroth, J.

67

Response to the comments from Drs Shimazawa and Ikeda

enthalten in: British journal of clinical pharmacology | 2013

von Shah, R. | Shah, D.

CommentOn: Br J Clin Pharmacol. 2012 Oct;74(4):698-721. - PMID 22591598

68

Cardiovascular safety of tyrosine kinase inhibitors : with a special focus on cardiac repolarisation (QT interval)

enthalten in: Drug safety | 2013

von Shah, R. | Morganroth, J. | Shah, D.

69

Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)

enthalten in: Drug safety | 2013

von Shah, R. | Morganroth, J. | Shah, D.

70

Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy

enthalten in: Drug safety | 2013

von Shah, D. | Shah, R. | Morganroth, J.